Focus |

Focus on cancer therapy

As our understanding of the mechanisms of cancer increases, so does our understanding of cancer therapies and responses to them. As part of our celebration for the 25th anniversary of Nature Medicine, we bring you a special focus on the most up-to-date approaches transforming the landscape of cancer therapy. Also check out the most recent clinical trials published in Nature Medicine and in Nature, as well as a selection of research in the emerging field of clinical genomics.

Reviews and Perspectives

  • Nature Medicine | Review Article

    The microbiome influences response to cancer therapy, including cancer immunotherapy, and also plays a role in therapeutic toxicity.

    • Beth A. Helmink
    • , M. A. Wadud Khan
    • , Amanda Hermann
    • , Vancheswaran Gopalakrishnan
    •  &  Jennifer A. Wargo
  • Nature Medicine | Perspective

    A neoadjuvant approach using combined anti-CTLA4/anti-PD1 treatment prior to lymph node surgery is evaluated in two phase I trials of later stage melanoma finding this a therapeutic angle worth pursuing.

    • Caroline Robert
  • Nature Medicine | Review Article

    The tumor immune microenvironment influences tumor progression and response to immunotherapy; its further characterization will improve therapeutic outcome.

    • Mikhail Binnewies
    • , Edward W. Roberts
    • , Kelly Kersten
    • , Vincent Chan
    • , Douglas F. Fearon
    • , Miriam Merad
    • , Lisa M. Coussens
    • , Dmitry I. Gabrilovich
    • , Suzanne Ostrand-Rosenberg
    • , Catherine C. Hedrick
    • , Robert H. Vonderheide
    • , Mikael J. Pittet
    • , Rakesh K. Jain
    • , Weiping Zou
    • , T. Kevin Howcroft
    • , Elisa C. Woodhouse
    • , Robert A. Weinberg
    •  &  Matthew F. Krummel

News

  • Nature Medicine | News Feature

    Cancer registries that track tumors as they spread could reveal how these growths metastasize

    • Brianna Abbott
  • Nature Medicine | Turning Points

    Georgina V. Long is co-medical director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research. She is the first woman president of the Society for Melanoma Research.

    • Georgina V. Long
  • Nature Medicine | Turning Points

    Samra Turajlic is a consultant medical oncologist at the Royal Marsden National Health Service Foundation Trust and a clinician–scientist at the Francis Crick Institute.

    • Samra Turajlic

Clinical Trials

  • Nature Medicine | Letter

    Neoadjuvant PD-1 blockade in patients with resectable melanoma followed by adjuvant maintenance results in early immunological effects driving clinical benefit and reveals transcriptional and genomic mechanisms of response.

    • Alexander C. Huang
    • , Robert J. Orlowski
    • , Xiaowei Xu
    • , Rosemarie Mick
    • , Sangeeth M. George
    • , Patrick K. Yan
    • , Sasikanth Manne
    • , Adam A. Kraya
    • , Bradley Wubbenhorst
    • , Liza Dorfman
    • , Kurt D’Andrea
    • , Brandon M. Wenz
    • , Shujing Liu
    • , Lakshmi Chilukuri
    • , Andrew Kozlov
    • , Mary Carberry
    • , Lydia Giles
    • , Melanie W. Kier
    • , Felix Quagliarello
    • , Suzanne McGettigan
    • , Kristin Kreider
    • , Lakshmanan Annamalai
    • , Qing Zhao
    • , Robin Mogg
    • , Wei Xu
    • , Wendy M. Blumenschein
    • , Jennifer H. Yearley
    • , Gerald P. Linette
    • , Ravi K. Amaravadi
    • , Lynn M. Schuchter
    • , Ramin S. Herati
    • , Bertram Bengsch
    • , Katherine L. Nathanson
    • , Michael D. Farwell
    • , Giorgos C. Karakousis
    • , E. John Wherry
    •  &  Tara C. Mitchell
  • Nature Medicine | Article

    Neoadjuvant pembrolizumab promotes a survival benefit with intratumoral and systemic immune responses in patients with recurrent glioblastoma.

    • Timothy F. Cloughesy
    • , Aaron Y. Mochizuki
    • , Joey R. Orpilla
    • , Willy Hugo
    • , Alexander H. Lee
    • , Tom B. Davidson
    • , Anthony C. Wang
    • , Benjamin M. Ellingson
    • , Julie A. Rytlewski
    • , Catherine M. Sanders
    • , Eric S. Kawaguchi
    • , Lin Du
    • , Gang Li
    • , William H. Yong
    • , Sarah C. Gaffey
    • , Adam L. Cohen
    • , Ingo K. Mellinghoff
    • , Eudocia Q. Lee
    • , David A. Reardon
    • , Barbara J. O’Brien
    • , Nicholas A. Butowski
    • , Phioanh L. Nghiemphu
    • , Jennifer L. Clarke
    • , Isabel C. Arrillaga-Romany
    • , Howard Colman
    • , Thomas J. Kaley
    • , John F. de Groot
    • , Linda M. Liau
    • , Patrick Y. Wen
    •  &  Robert M. Prins
  • Nature Medicine | Article

    Fry et al. report the first results from a human trial of a CD22-directed chimeric antigen receptor (CAR) T cell therapy providing evidence of efficacy in the treatment of pre–B cell acute lymphoblastic leukemia that is immunotherapy-naive or resistant to CD19-directed CAR T cells.

    • Terry J Fry
    • , Nirali N Shah
    • , Rimas J Orentas
    • , Maryalice Stetler-Stevenson
    • , Constance M Yuan
    • , Sneha Ramakrishna
    • , Pamela Wolters
    • , Staci Martin
    • , Cindy Delbrook
    • , Bonnie Yates
    • , Haneen Shalabi
    • , Thomas J Fountaine
    • , Jack F Shern
    • , Robbie G Majzner
    • , David F Stroncek
    • , Marianna Sabatino
    • , Yang Feng
    • , Dimiter S Dimitrov
    • , Ling Zhang
    • , Sang Nguyen
    • , Haiying Qin
    • , Boro Dropulic
    • , Daniel W Lee
    •  &  Crystal L Mackall
  • Nature Medicine | Letter

    Neoadjuvant nivolumab treatment in patients with glioblastoma induces intratumoral immune activation and underscores the need for rationale-based combination approaches for improving clinical responses.

    • Kurt A. Schalper
    • , Maria E. Rodriguez-Ruiz
    • , Ricardo Diez-Valle
    • , Alvaro López-Janeiro
    • , Angelo Porciuncula
    • , Miguel A. Idoate
    • , Susana Inogés
    • , Carlos de Andrea
    • , Ascensión López-Diaz de Cerio
    • , Sonia Tejada
    • , Pedro Berraondo
    • , Franz Villarroel-Espindola
    • , Jungmin Choi
    • , Alfonso Gúrpide
    • , Miriam Giraldez
    • , Iosune Goicoechea
    • , Jaime Gallego Perez-Larraya
    • , Miguel F. Sanmamed
    • , Jose L. Perez-Gracia
    •  &  Ignacio Melero
  • Nature Medicine | Letter

    Initial results from a first-in-human study show that PET imaging with PD-L1 antibodies outperforms immunohistochemistry- or RNA-sequencing-based biomarkers for prediction of clinical response to immunotherapy.

    • Frederike Bensch
    • , Elly L. van der Veen
    • , Marjolijn N. Lub-de Hooge
    • , Annelies Jorritsma-Smit
    • , Ronald Boellaard
    • , Iris C. Kok
    • , Sjoukje F. Oosting
    • , Carolina P. Schröder
    • , T. Jeroen N. Hiltermann
    • , Anthonie J. van der Wekken
    • , Harry J. M. Groen
    • , Thomas C. Kwee
    • , Sjoerd G. Elias
    • , Jourik A. Gietema
    • , Sandra Sanabria Bohorquez
    • , Alex de Crespigny
    • , Simon-Peter Williams
    • , Christoph Mancao
    • , Adrienne H. Brouwers
    • , Bernard M. Fine
    •  &  Elisabeth G. E. de Vries
  • Nature Medicine | Letter

    Radiotherapy-induced abscopal responses enhance the efficacy of anti-CTLA-4 in patients with non-small-cell lung cancer.

    • Silvia C. Formenti
    • , Nils-Petter Rudqvist
    • , Encouse Golden
    • , Benjamin Cooper
    • , Erik Wennerberg
    • , Claire Lhuillier
    • , Claire Vanpouille-Box
    • , Kent Friedman
    • , Lucas Ferrari de Andrade
    • , Kai W. Wucherpfennig
    • , Adriana Heguy
    • , Naoko Imai
    • , Sacha Gnjatic
    • , Ryan O. Emerson
    • , Xi Kathy Zhou
    • , Tuo Zhang
    • , Abraham Chachoua
    •  &  Sandra Demaria

Related content

  • Nature Medicine | Letter

    Genomic, transcriptomic, and microenvironmental analyses of samples from patients with glioblastoma treated with nivolumab or pembrolizumab identifies features associated with treatment response that may help in refining patient stratification.

    • Junfei Zhao
    • , Andrew X. Chen
    • , Robyn D. Gartrell
    • , Andrew M. Silverman
    • , Luis Aparicio
    • , Tim Chu
    • , Darius Bordbar
    • , David Shan
    • , Jorge Samanamud
    • , Aayushi Mahajan
    • , Ioan Filip
    • , Rose Orenbuch
    • , Morgan Goetz
    • , Jonathan T. Yamaguchi
    • , Michael Cloney
    • , Craig Horbinski
    • , Rimas V. Lukas
    • , Jeffrey Raizer
    • , Ali I. Rae
    • , Jinzhou Yuan
    • , Peter Canoll
    • , Jeffrey N. Bruce
    • , Yvonne M. Saenger
    • , Peter Sims
    • , Fabio M. Iwamoto
    • , Adam M. Sonabend
    •  &  Raul Rabadan
  • Nature Medicine | Article

    A blood-based DNA sequencing assay to infer tumor mutational burden in the absence of tumor biopsy predicts response to PD-L1 blockade in patients with non-small-cell lung cancer.

    • David R. Gandara
    • , Sarah M. Paul
    • , Marcin Kowanetz
    • , Erica Schleifman
    • , Wei Zou
    • , Yan Li
    • , Achim Rittmeyer
    • , Louis Fehrenbacher
    • , Geoff Otto
    • , Christine Malboeuf
    • , Daniel S. Lieber
    • , Doron Lipson
    • , Jacob Silterra
    • , Lukas Amler
    • , Todd Riehl
    • , Craig A. Cummings
    • , Priti S. Hegde
    • , Alan Sandler
    • , Marcus Ballinger
    • , David Fabrizio
    • , Tony Mok
    •  &  David S. Shames
  • Nature Medicine | Resource

    Comprehensive integration of mutational and structural alterations in clinically-annotated DLBCL patient samples provides a novel molecular classification of the disease.

    • Bjoern Chapuy
    • , Chip Stewart
    • , Andrew J. Dunford
    • , Jaegil Kim
    • , Atanas Kamburov
    • , Robert A. Redd
    • , Mike S. Lawrence
    • , Margaretha G. M. Roemer
    • , Amy J. Li
    • , Marita Ziepert
    • , Annette M. Staiger
    • , Jeremiah A. Wala
    • , Matthew D. Ducar
    • , Ignaty Leshchiner
    • , Ester Rheinbay
    • , Amaro Taylor-Weiner
    • , Caroline A. Coughlin
    • , Julian M. Hess
    • , Chandra S. Pedamallu
    • , Dimitri Livitz
    • , Daniel Rosebrock
    • , Mara Rosenberg
    • , Adam A. Tracy
    • , Heike Horn
    • , Paul van Hummelen
    • , Andrew L. Feldman
    • , Brian K. Link
    • , Anne J. Novak
    • , James R. Cerhan
    • , Thomas M. Habermann
    • , Reiner Siebert
    • , Andreas Rosenwald
    • , Aaron R. Thorner
    • , Matthew L. Meyerson
    • , Todd R. Golub
    • , Rameen Beroukhim
    • , Gerald G. Wulf
    • , German Ott
    • , Scott J. Rodig
    • , Stefano Monti
    • , Donna S. Neuberg
    • , Markus Loeffler
    • , Michael Pfreundschuh
    • , Lorenz Trümper
    • , Gad Getz
    •  &  Margaret A. Shipp
  • Nature Medicine | Article

    An exploratory randomized controlled clinical trial of renal cell carcinoma identifies molecular patterns distinguishing responders to immune checkpoint blockade alone or combined with angiogenesis inhibitor versus angiogenesis inhibitor alone.

    • David F. McDermott
    • , Mahrukh A. Huseni
    • , Michael B. Atkins
    • , Robert J. Motzer
    • , Brian I. Rini
    • , Bernard Escudier
    • , Lawrence Fong
    • , Richard W. Joseph
    • , Sumanta K. Pal
    • , James A. Reeves
    • , Mario Sznol
    • , John Hainsworth
    • , W. Kimryn Rathmell
    • , Walter M. Stadler
    • , Thomas Hutson
    • , Martin E. Gore
    • , Alain Ravaud
    • , Sergio Bracarda
    • , Cristina Suárez
    • , Riccardo Danielli
    • , Viktor Gruenwald
    • , Toni K. Choueiri
    • , Dorothee Nickles
    • , Suchit Jhunjhunwala
    • , Elisabeth Piault-Louis
    • , Alpa Thobhani
    • , Jiaheng Qiu
    • , Daniel S. Chen
    • , Priti S. Hegde
    • , Christina Schiff
    • , Gregg D. Fine
    •  &  Thomas Powles
  • Nature Medicine | Article

    MSK-IMPACT is a clinical sequencing platform able to detect genomic mutations, copy number alterations and structural variants in a panel of cancer-related genes. This assay is implemented prospectively to inform patient enrollment in genomically matched clinical trials at Memorial Sloan Kettering Cancer Center (MSKCC). Sequencing results of tumor and matched normal tissue from a cohort of >10,000 patients with detailed clinical annotation provide an overview of the genomic landscape of advanced solid cancers and bring new insights into molecularly guided cancer therapy.

    • Ahmet Zehir
    • , Ryma Benayed
    • , Ronak H Shah
    • , Aijazuddin Syed
    • , Sumit Middha
    • , Hyunjae R Kim
    • , Preethi Srinivasan
    • , Jianjiong Gao
    • , Debyani Chakravarty
    • , Sean M Devlin
    • , Matthew D Hellmann
    • , David A Barron
    • , Alison M Schram
    • , Meera Hameed
    • , Snjezana Dogan
    • , Dara S Ross
    • , Jaclyn F Hechtman
    • , Deborah F DeLair
    • , JinJuan Yao
    • , Diana L Mandelker
    • , Donavan T Cheng
    • , Raghu Chandramohan
    • , Abhinita S Mohanty
    • , Ryan N Ptashkin
    • , Gowtham Jayakumaran
    • , Meera Prasad
    • , Mustafa H Syed
    • , Anoop Balakrishnan Rema
    • , Zhen Y Liu
    • , Khedoudja Nafa
    • , Laetitia Borsu
    • , Justyna Sadowska
    • , Jacklyn Casanova
    • , Ruben Bacares
    • , Iwona J Kiecka
    • , Anna Razumova
    • , Julie B Son
    • , Lisa Stewart
    • , Tessara Baldi
    • , Kerry A Mullaney
    • , Hikmat Al-Ahmadie
    • , Efsevia Vakiani
    • , Adam A Abeshouse
    • , Alexander V Penson
    • , Philip Jonsson
    • , Niedzica Camacho
    • , Matthew T Chang
    • , Helen H Won
    • , Benjamin E Gross
    • , Ritika Kundra
    • , Zachary J Heins
    • , Hsiao-Wei Chen
    • , Sarah Phillips
    • , Hongxin Zhang
    • , Jiaojiao Wang
    • , Angelica Ochoa
    • , Jonathan Wills
    • , Michael Eubank
    • , Stacy B Thomas
    • , Stuart M Gardos
    • , Dalicia N Reales
    • , Jesse Galle
    • , Robert Durany
    • , Roy Cambria
    • , Wassim Abida
    • , Andrea Cercek
    • , Darren R Feldman
    • , Mrinal M Gounder
    • , A Ari Hakimi
    • , James J Harding
    • , Gopa Iyer
    • , Yelena Y Janjigian
    • , Emmet J Jordan
    • , Ciara M Kelly
    • , Maeve A Lowery
    • , Luc G T Morris
    • , Antonio M Omuro
    • , Nitya Raj
    • , Pedram Razavi
    • , Alexander N Shoushtari
    • , Neerav Shukla
    • , Tara E Soumerai
    • , Anna M Varghese
    • , Rona Yaeger
    • , Jonathan Coleman
    • , Bernard Bochner
    • , Gregory J Riely
    • , Leonard B Saltz
    • , Howard I Scher
    • , Paul J Sabbatini
    • , Mark E Robson
    • , David S Klimstra
    • , Barry S Taylor
    • , Jose Baselga
    • , Nikolaus Schultz
    • , David M Hyman
    • , Maria E Arcila
    • , David B Solit
    • , Marc Ladanyi
    •  &  Michael F Berger
  • Nature Medicine | Analysis

    HRDetect represents a model integrating whole-genome sequencing mutation signatures associated with BRCA1 and BRCA2 deficiency. The implementation of this predictor across different tumor types identifies a larger proportion of patients displaying ‘BRCAness’ than previously recognized; they might derive benefit from platinum and PARP-inhibitor therapies.

    • Helen Davies
    • , Dominik Glodzik
    • , Sandro Morganella
    • , Lucy R Yates
    • , Johan Staaf
    • , Xueqing Zou
    • , Manasa Ramakrishna
    • , Sancha Martin
    • , Sandrine Boyault
    • , Anieta M Sieuwerts
    • , Peter T Simpson
    • , Tari A King
    • , Keiran Raine
    • , Jorunn E Eyfjord
    • , Gu Kong
    • , Åke Borg
    • , Ewan Birney
    • , Hendrik G Stunnenberg
    • , Marc J van de Vijver
    • , Anne-Lise Børresen-Dale
    • , John W M Martens
    • , Paul N Span
    • , Sunil R Lakhani
    • , Anne Vincent-Salomon
    • , Christos Sotiriou
    • , Andrew Tutt
    • , Alastair M Thompson
    • , Steven Van Laere
    • , Andrea L Richardson
    • , Alain Viari
    • , Peter J Campbell
    • , Michael R Stratton
    •  &  Serena Nik-Zainal